Navigation Links
Lazy eye treatment times could be drastically reduced, new research shows

Treatment times for amblyopia more commonly known as 'lazy eye' could be drastically reduced thanks to research carried out at The University of Nottingham.

Amblyopia is thought to affect up to 2.5 per cent of people and accounts for around 90 per cent of all children's eye appointments in the UK. Occlusion therapy patching the normal eye for lengthy periods to 'train' the affected eye is the main treatment for amblyopia. However, this method can be distressing to children, is unpopular with parents and can adversely effect educational development. This type of therapy has been used in various forms since 1743 and has long been considered to only be effective up until late childhood.

The new treatments developed in the Visual Neuroscience Group in the University's School of Psychology have not only reduced potential treatment times by an unprecedented amount, they have also proved that it is possible to treat amblyopia in adults. Early results suggest gains, that would have required around 120 hours of occlusion therapy to achieve, can be produced after just 10 hours.

Adult test subjects have undertaken challenging visual tasks under computer-controlled conditions. Academics hope that these promising results could be used to develop a child-friendly game that could treat amblyopia. There is also the potential to use these new treatments to supplement occlusion therapy.

The 60,000 project A Study of Perceptual Learning Effects in Amblyopia has been funded by the College of Optometrists. Amblyopia is a developmental problem in the brain, not the eye. The part of the brain dealing with vision from the affected eye develops abnormally as a result of atypical visual experience early in life. This results in markedly different levels of vision in each eye which cannot be remedied with spectacles.

As well as looking at potential treatments for the condition, the study examines the level of neural plasticity in the adult brain the ability of a neural system to change with experience.

The work is being carried out by Andrew Astle, a PhD student at the University.

"The results so far show a drastic improvement on patching, and disprove the long-held belief that adults cannot be treated for this type of condition," Andrew said. "However, the study is not complete and we're still looking for subjects to take part in the tests."

Work set to start in spring 2009 at the University will build on Andrew's results, examining amblyopia in children and examining the functional and structural organisation of the visual cortex. This EU-wide study has been funded by a European Consortium FP7 grant to the tune of 2.6m Euro. Professor Paul McGraw and Dr Ben Webb in the Visual Neuroscience Group will look at the effects and treatment of amblyopia in children. Other European institutions, including the University of Florence, the Max Planck Institute for Neuroscience and University College London, will examine the condition from the molecular level to its behavioural impact on animal models.

It is thought that results from this study could be translated to other conditions where recovery is limited due to restricted neural plasticity including brain tumours, stroke, degenerative diseases and trauma.

Professor McGraw said "Andrew's results suggest that the adult amblyopic visual system retains a great deal more neural plasticity than previously thought. Harnessing this plasticity offers a new way of treating this common condition and opens the door to developing novel pharmacological and behavioural interventions for a range of neurological deficits."


Contact: Andrew Astle
University of Nottingham

Related medicine news :

1. Childrens cancer group recommends global evaluation system for neuroblastoma to improve treatment
2. UK kidney cancer patients face toxic, out-dated treatments with little hope of change
3. Launches Doctor-Driven Biomedical Autism Treatment Website
4. Juva Skin Center's Laser Skin Treatments Take an Innovative Leap with Pixel CO2 Device
5. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
6. Confusing risk information may lead breast cancer patients to make poor treatment choices
7. Precious metal could lead to next generation of cancer treatments
8. The St. John-Clark Pain Treatment Center Forms Manual Therapy 'Dream Team'
9. Novel treatments show improvements in survival and response rates for leukemia and lymphoma
10. Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma
11. Treatment Options Are Many for Prostate Cancer
Post Your Comments:
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December ... the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis ... celebrates exceptional special needs providers that excel in synthesizing the areas of clinical ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VIEJO, Calif. , Dec. 1, 2015 /PRNewswire/ ... the prevalence of symptoms for pseudobulbar affect (PBA), ... outbursts of laughing and/or crying resulting from certain ... use of antipsychotic medications in nursing home residents, ... Geriatric Psychiatry. The study showed that almost one ...
(Date:12/1/2015)... , Dec. 1, 2015 Research and ... of the "2016 Global Enteric Disease Testing ... Salmonella, Shigella, Vibrio, Yersinia--France, Germany, Italy, Japan, Spain, ... Japan . --> ... The report is based on a combination ...
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
Breaking Medicine Technology: